Th17-Driven NHP Immunology Models | Translational Autoimmune Research At Prisys Biotech

Understanding and modulating the T helper 17 (Th17) pathway remains a central challenge in the development of therapies for autoimmune and chronic inflammatory diseases. Prisys Biotech has established a dedicated non-human primate (NHP) model platform designed to induce and characterize Th17-driven immune responses in cynomolgus monkeys. This platform provides a translationally relevant tool for evaluating novel therapeutics targeting the IL-17/IL-23 axis and other pathways implicated in Th17 dysregulation.

Th17 cells and their signature cytokines-particularly IL-17A-play a dual role in host defense and pathological inflammation. While essential for protection against extracellular bacteria and fungi, excessive or dysregulated Th17 activity contributes to the pathogenesis of diseases such as psoriasis, ankylosing spondylitis, rheumatoid arthritis, and multiple sclerosis.

Rodent models are widely used but often fail to reproduce key features of human Th17 biology, limiting their predictive value in translational research. Given the immune system similarity between cynomolgus monkeys and humans, an NHP-based Th17 model offers a more accurate system for evaluating drug efficacy and immunomodulatory mechanisms.

Prisys Biotech has developed a controlled immunization strategy that reliably induces Th17-biased immune responses in cynomolgus monkeys. This platform can be tailored to support early proof-of-concept, mechanism-of-action studies, and pharmacodynamic assessments for immunomodulatory drug candidates.

Key Features and Advantages

1. Multiple Immunization Routes to Shape Th17 Responses

The platform supports intranasal and intramuscular immunization protocols, enabling investigators to evaluate both mucosal and systemic immune activation. Intranasal immunization has shown specific value in enhancing mucosal Th17 responses, providing a model suitable for testing inhaled, mucosa-targeted, or vaccine-based interventions.

2. Comprehensive Immunophenotyping and Cytokine Profiling

A structured analytical workflow allows multidimensional assessment of immune activation:

• Serum cytokine kinetics including IL-17A, IFN-γ, IL-4, and related markers across the Th1/Th2/Th17 spectrum.
• Flow cytometric analysis of PBMCs, quantifying CD3⁺CD4⁺IL-17A⁺ Th17 populations to monitor cellular responses at high resolution.
• Tissue-level immune assessment, such as splenic or pulmonary lymphocyte profiling, to capture cytokine production at local immune sites.

This layered approach offers a detailed view of Th17 pathway activity and enables robust evaluation of therapeutic modulation.

3. Optional Viral Challenge for Functional Readouts

For vaccine or immune-protection studies, the platform can incorporate intranasal viral challenge (e.g., influenza virus) following immunization. This provides a functional assessment of mucosal immunity and helps quantify the contribution of Th17 responses to protective efficacy.

4. High Translational Relevance for Drug Development

Due to the close immunological similarity between NHPs and humans, the Th17 model provides pharmacodynamic and immunogenicity readouts that better predict clinical performance. This reduces uncertainty in progression decisions and strengthens data packages for IND submissions.

• Evaluation of IL-17/IL-23 pathway inhibitors, monoclonal antibodies, or small-molecule modulators
• Assessment of next-generation vaccines, especially those aiming to elicit mucosal Th17 immunity
• Disease-mechanism research focused on Th17-mediated pathology
• Exploration of immune system dynamics under targeted intervention

The flexibility and depth of the platform make it suitable for both exploratory and late-preclinical studies.

Collaborate with Prisys Biotech

Prisys Biotech supports global pharmaceutical and biotech partners by providing scientifically rigorous, clinically relevant NHP models for immunology and autoimmune drug development. Our Th17 platform is designed to facilitate clear go/no-go decisions, deepen mechanistic insights, and accelerate the translation of innovative therapies toward clinical evaluation.

For further scientific discussion or to explore customized study designs, please contact:
Email: bd@prisysbiotech.com
Website: www.prisysbiotech.com